Innovent and Takeda Close $11.4 Bln Deal for IO and ADC Therapies

Innovent Biologics and Takeda have closed an $11.4 billion collaboration to develop and commercialize next-generation immuno-oncology and antibody-drug conjugate therapies. The partnership includes co-development of IBI363 globally, with Takeda leading commercialization outside Greater China and the U.S. Takeda also secured exclusive global rights to develop and commercialize IBI343 outside Greater China and an option for IBI3001 outside Greater China. Innovent is eligible for up to $10.2 billion in milestone payments and potential royalties.